Mayroy

Mayroy is a Luxembourg-based private holding company that serves as the primary controlling shareholder of Ipsen, a leading global biopharmaceutical group. Through its majority stake in Ipsen, Mayroy is strategically positioned in the development and commercialization of innovative medicines across oncology, neuroscience, and rare diseases. The company represents the long-term interests of the Beaufour family, who founded the Ipsen group and continue to guide its strategic direction. Mayroy's portfolio includes high-profile assets such as Cabometyx for renal cell carcinoma and Somatuline for neuroendocrine tumors. As a central entity in the Ipsen corporate structure, Mayroy plays a critical role in the financial oversight and governance of its pharmaceutical operations. The company's value is driven by a robust pipeline of over 25 programs and a strong commercial presence in over 100 countries.